Lucid DiagnosticsLUCD +2.31%20 EV-to-EBITDA is -4.49 as of Jul. 09, 2026. GuruFocus rates LUCD with a GF Score™ of 20/100 and a GF Value™ of $0.82 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 511 Medical Devices & Instruments companies, Lucid Diagnostics ranks worse than 195694.52% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lucid Diagnostics's enterprise value is $197.96 Mil.
Lucid Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-44.12 Mil. Therefore, Lucid Diagnostics's EV-to-EBITDA for today is -4.49.
The historical rank and industry rank for Lucid Diagnostics's EV-to-EBITDA or its related term are showing as below:
LUCD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.31 Med: -1.92 Max: -0.43
Current: -4.49
During the past 7 years, the highest EV-to-EBITDA of Lucid Diagnostics was -0.43. The lowest was -21.31. And the median was -1.92.
LUCD's EV-to-EBITDA is ranked worse than 100% of 511
companies
in the Medical Devices & Instruments industry
Industry Median: 14.11
vs LUCD: -4.49
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lucid Diagnostics's PE Ratio (TTM) for today is calculated as:
Lucid Diagnostics's share price for today is $0.9801.
Lucid Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.450.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Lucid Diagnostics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Lucid Diagnostics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lucid Diagnostics EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lucid Diagnostics's EV-to-EBITDA falls into.
Lucid Diagnostics's current Enterprise Value is $197.96 Mil.
Lucid Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-44.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lucid Diagnostics (LUCD) has a EV-to-EBITDA of -4.49 as of Jul. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lucid Diagnostics. According to the industry distribution chart, Lucid Diagnostics ranks #999999 out of 511 companies in the Medical Devices & Instruments industry.
Is Lucid Diagnostics' EV-to-EBITDA too high?
Lucid Diagnostics' current EV-to-EBITDA is -4.49. Based on the distribution chart, Lucid Diagnostics ranks #999999 out of 511 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Lucid Diagnostics has a GF Score™ of 20/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' EV-to-EBITDA compare to QTRX and INFU?
According to the Medical Devices & Instruments industry distribution chart, Lucid Diagnostics ranks #999999 out of 511 companies for EV-to-EBITDA. This places Lucid Diagnostics in the lower half of its industry. The industry median EV-to-EBITDA is 14.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.11, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lucid Diagnostics. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lucid Diagnostics's current EV-to-EBITDA is -4.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.82, compared to a current price of $0.98 — trading 19.5% above its estimated fair value. The current EV-to-EBITDA is -4.49. Lucid Diagnostics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current EV-to-EBITDA is -4.49 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lucid Diagnostics (LUCD) Overvalued in 2026?
Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued.
The current stock price of $0.98 is trading 19.5% above its estimated GF Value™ of $0.82.
GuruFocus considers Lucid Diagnostics to be Modestly Overvalued.
Key valuation signals for LUCD:
EV-to-EBITDA: -4.49
GF Value™: $0.82 vs. price of $0.98 (19.5% above fair value)
No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
20GF Score
Get the complete analysis for LUCD
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUCD has been successfully added to your 
